OFIX Orthofix Medical Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 884624 · Fiscal year ends 12/23
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.1%
TTM net income YoY62.2%
TTM EPS YoY63.7%
Revenue 3-yr CAGR7.7%
Net income 3-yr CAGR—
Margins
Gross margin70.9%
Operating margin-2.5%
Net margin-5.4%
FCF margin-5.3%
EBITDA margin3.9%
Returns
ROE-10.3%
ROA-5.3%
ROIC (approx.)-2.9%
Asset turnover0.99x
Leverage & solvency
Liabilities / assets49.8%
Debt / equity0.52x
Current ratio3.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.09x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue5.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $822.31M | $799.49M |
| Cost of revenue | $256.30M | $253.61M |
| Gross profit | $566.02M | $545.88M |
| R&D expense | $65.85M | $73.64M |
| SG&A expense | $554.33M | $532.52M |
| Operating income | -$81.43M | -$84.62M |
| Pretax income | -$90.81M | -$123.88M |
| Income tax | $1.38M | $2.12M |
| Net income | -$92.19M | -$126.00M |
| EBITDA | -$4.11M | -$24.56M |
| EPS (basic) | -2.33 | -3.30 |
| EPS (diluted) | -2.33 | -3.30 |
| Weighted avg. shares (diluted) | 39.60M | 38.13M |
| Banking | ||
| Net interest income | -$17.49M | -$29.63M |
| Provision for credit losses | $2.25M | $2.00M |
| Balance sheet | ||
| Cash & equivalents | $82.03M | $83.24M |
| Receivables | $135.75M | $134.71M |
| Inventory | $172.32M | $189.45M |
| Current assets | $416.85M | $433.29M |
| PP&E, net | $129.40M | $139.80M |
| Goodwill | $194.93M | $194.93M |
| Intangibles | $72.77M | $98.80M |
| Total assets | $850.65M | $893.29M |
| Current liabilities | $170.48M | $168.63M |
| Short-term debt | $0 | $0 |
| Long-term debt | $157.39M | $157.01M |
| Total debt | $157.39M | $157.01M |
| Total liabilities | $400.61M | $390.17M |
| Shareholders' equity | $450.04M | $503.12M |
| Net debt | $75.37M | $73.78M |
| Shares outstanding | 39.83M | 38.49M |
| Cash flow statement | ||
| Operating cash flow | $33.35M | $25.79M |
| Capital expenditure | $34.63M | $34.88M |
| Free cash flow | -$1.28M | -$9.09M |
| Investing cash flow | -$34.60M | -$27.58M |
| Financing cash flow | -$786,000 | $50.71M |
| Depreciation & amortization | $77.32M | $60.06M |
| Stock-based compensation | $28.69M | $32.45M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.